Neurocrine Biosciences (NBIX) and Sosei Group said Monday they signed a collaboration and licensing agreement to develop new compounds for the treatment of...
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $150, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $100 to $150, according to analysts polled by Capital IQ....
Health care stocks were well off their best levels of the day ahead of Tuesday's close, with the NYSE Health Care Index up 0.6% while the Health Care...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 12/01/2021 3 |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Vice President-Information Technology & Operations | Bill Wilson |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Price Open | $83.39 |
| Previous Close | $80.79 |
| 52 Week Range | $79.89 - 120.27 |
| Market Capitalization | $7.7 B |
| Shares Outstanding | 94.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 19.03 |
| Earnings per Share | $4.83 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 41.59% |
| Return on Equity | 35.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
